Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

A day after Novo Nordisk (NVO) CEO Lars Fruergaard Jørgensen was grilled by a U.S. Senate committee, Cantor Fitzgerald ...

Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating on the shares of Eli Lilly And Co (NYSE:LLY) and maintained a price target of $885. The company is slated to report its second ...

However, Cantor Fitzgerald’s Louise Chen said beat and raise supported her bullish thesis on PFE. “We continue to think there is a lot of value to be unlocked for PFE shares,” Chen added.

Louise Chen is an analyst at Cantor Fitzgerald. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Hookipa Pharma (HOOK – Research Report) ...

Cantor Fitzgerald analyst Louise Chen maintained a Buy rating on Pfizer (PFE – Research Report) yesterday and set a price target of $45.00. The company’s shares closed yesterday at $28.64.

Meanwhile, Eli Lilly has orforglipron, an oral GLP-1 in phase 3. At the Seeking Alpha Investing Summit in June, Louise Chen, managing director at Cantor Fitzgerald, said orforglipron is ahead in ...

Thank you for standing by. Welcome to the Merck & Co. Q3 sales and earnings conference call. (Operator Instructions) This call is being recorded. If you have any objections, you may disconnect at this ...

Third quarter sales of Novo’s in-demand obesity drug totaled $2.5 billion, roughly 81% higher than the same period in 2023 and nearly doubling the total for Lilly’s Zepbound.